Benzene Ring Containing Patents (Class 514/585)
-
Publication number: 20030236287Abstract: The invention provides compounds of Formula I: 1Type: ApplicationFiled: April 25, 2003Publication date: December 25, 2003Inventors: David W. Piotrowski, Bruce N. Rogers, William W. McWhorter, Daniel Patrick Walker, Jeffrey W. Corbett, Vincent E. Groppi, Daniel G. Rudmann
-
Publication number: 20030207939Abstract: The present invention relates to a urea derivative of the formula (1) 1Type: ApplicationFiled: February 5, 2003Publication date: November 6, 2003Inventors: Seigo Ishibuchi, Hiroshi Sumichika, Katsuhiko Itoh, Yoichi Naka
-
Publication number: 20030195231Abstract: Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism:Type: ApplicationFiled: July 2, 2002Publication date: October 16, 2003Inventors: Hiroshi Takemoto, Takeshi Shiota, Masami Takayama
-
Patent number: 6627771Abstract: The instant invention is improved gamma amino butyric acid analogs, processes for their preparation, and methods of using them as agents for treating epilepsy and other neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal damage, and inflammation.Type: GrantFiled: April 13, 2001Date of Patent: September 30, 2003Assignee: Pfizer IncInventors: Thomas Richard Belliotti, David Juergen Wustrow
-
Patent number: 6620806Abstract: The present invention provides methods and kits for improving or maintaining vascular health, including preventing myocardial infarction or stroke; maintaining or improving vascular reactivity; treating acute or chronic renal failure, peripheral arterial occlusive disease, coronary artery disease, or Raynaud's phenomenon; or lowering plasma levels of Lp(a) using an estrogen agonist/antagonist.Type: GrantFiled: October 15, 2001Date of Patent: September 16, 2003Assignee: Pfizer Inc.Inventors: Wesley W. Day, Andrew G. Lee, David D. Thompson
-
Publication number: 20030158226Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.Type: ApplicationFiled: September 17, 2002Publication date: August 21, 2003Applicant: Roche Bioscience, a division of Syntex (U.S.A.) LLCInventors: Paula Nanette Belloni, Denis John Kertesz, Michael Klaus, Jean-Marc Lapierre
-
Patent number: 6608052Abstract: Disclosed are novel aromatic compounds of the formula(I) wherein G, E, W, Ar, X, Y and Z. The compounds are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.Type: GrantFiled: April 13, 2001Date of Patent: August 19, 2003Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Steffen Breitfelder, Pier F. Cirillo, John R. Regan
-
Publication number: 20030130309Abstract: Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein.Type: ApplicationFiled: July 1, 2002Publication date: July 10, 2003Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Neil Moss, John Robinson Regan
-
Publication number: 20030130320Abstract: Phenylalanine derivatives of the following formulae and analogues thereof have an antagonistic activity to &agr;4 integrin. They are used as therapeutic agents for various diseases concerning &agr;4 integrin.Type: ApplicationFiled: September 23, 2002Publication date: July 10, 2003Applicant: AJINOMOTO CO. INCInventors: Nobuyasu Suzuki, Toshihiko Yoshimura, Hiroyuki Izawa, Shingo Makino, Eiji Nakanishi, Masahiro Murata, Takashi Tsuji
-
Publication number: 20030125383Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.Type: ApplicationFiled: September 17, 2002Publication date: July 3, 2003Applicant: Roche Bioscience, a division of Syntex (U.S.A.) LLCInventors: Michael Klaus, Jean-Marc Lapierre
-
Publication number: 20030114532Abstract: A method is provided for inhibiting free radical degradation in the skin of a human or nonhuman animal comprising contacting the skin with a skin treatment composition having a concentration of a 1-(3-methoxybenzyl)-3-substituted thiourea compound effective for inhibiting free radical generation. Skin protecting compositions comprising a free radical inhibiting concentration of a 1-(3-methoxybenzyl)-3-substituted thiourea compound, and optionally a sunscreeen composition, are also provided.Type: ApplicationFiled: January 8, 2003Publication date: June 19, 2003Applicant: Fan Tech, Ltd.Inventors: Alan Wohlman, Anthony J. O'Lenick
-
Patent number: 6573284Abstract: Novel pro-drugs and assay reagents are provided which are useful as therapeutic agents especially for delivery and targetting therapeutically active agents to melanoma cells. The pro-drugs and assay reagents are substrates for tyrosinase and may be represented by the formula TyrX—B—ThrAg*. The compounds of formula TyrX—B—ThrAg* are capable of releasing a therapeutically active agent or assayable substance (ThrAg) at a desired location. TyrX— being a residue of an optionally substituted tyrosine analogue.Type: GrantFiled: June 14, 1999Date of Patent: June 3, 2003Inventors: Patrick Anthony Riley, Andrew Photiou, Tariq Hussain Khan, Helen Mary Osborn
-
Publication number: 20030092766Abstract: Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.Type: ApplicationFiled: October 19, 2001Publication date: May 15, 2003Inventors: Ken Chow, Daniel W. Gil, Wenkui Ken Fang, Michael E. Garst, Larry A. Wheeler
-
Patent number: 6545052Abstract: A method is provided for inhibiting free radical degradation in the skin of a human or nonhuman animal comprising contacting the skin with a skin treatment composition having a concentration of a 1-(3-methoxybenzyl)-3-substituted thiourea compound effective for inhibiting free radical generation. Skin protecting compositions comprising a free radical inhibiting concentration of a 1-(3-methoxybenzyl)-3-substituted thiourea compound, and optionally a sunscreeen composition, are also provided.Type: GrantFiled: November 29, 2000Date of Patent: April 8, 2003Assignee: Fan Tech, Ltd.Inventors: Alan Wohlman, Anthony J. O'Lenick, Jr.
-
Publication number: 20030036532Abstract: The invention relates to the use of compounds of formula (I), wherein n=0-3; R1, R2=H, alkyl, aryl, heteroaryl, acyl; R3=H, halogen, alkyl, aryl, heteroaryl, arylalkyl, acyl, CN, NO2, R4—X—; R4=H, alkyl, aryl, heteroaryl, aralkyl, acyl; X=NH, O, S, SO2, NHSO2, OSO2, and A, B, C=organic groups. The inventive compounds are used for the prophylaxis and the therapeutic treatment of infectious processes, especially of infectious processes caused by parasites. The invention further relates to medicaments that contain the inventive compounds.Type: ApplicationFiled: August 23, 2002Publication date: February 20, 2003Inventors: Hassan Jomaa, Martin Schlitzer, Jochen Wiesner
-
Patent number: 6479458Abstract: A method for preventing retinal ganglion cell depth, associated with glaucoma, in an animal of the mammalian species, including humans, comprising the step of administering to ganglion cells and their axons (optic nerve) of said mammal a pharmaceutical composition which comprises as its active ingredient one or more compounds having activity for blocking a reverse mode of the sodium/calcium exchanger.Type: GrantFiled: November 8, 2001Date of Patent: November 12, 2002Assignee: Allergan, Inc.Inventors: Joseph S. Adorante, George R. Ehring, Kara L. Kopper
-
Patent number: 6423870Abstract: The invention concerns compounds of formula (I) in which: A forms a tricyclic system of formula A1, A2, A3 or A4; R1 represents a hydrogen atom, an alkyl, hydroxy, alkoxy or oxo group; (R2)m and (R3)m′ are such as defined in the description; n represents an integer such that 0≦n≦3; p represents an integer such as defined in the description; B represents a group (a) or (b). The invention is useful for preparing medicines.Type: GrantFiled: July 14, 2000Date of Patent: July 23, 2002Assignee: Les Laboratoires ServierInventors: Michel Langlois, Monique Mathe-Allainmat, Carole Jellimann, Jean Andrieux, Caroline Bennejean, Pierre Renard, Philippe Delagrange
-
Publication number: 20020094342Abstract: A method is provided for inhibiting free radical degradation in the skin of a human or nonhuman animal comprising contacting the skin with a skin treatment composition having a concentration of a 1-(3-methoxybenzyl)-3-substituted thiourea compound effective for inhibiting free radical generation. Skin protecting compositions comprising a free radical inhibiting concentration of a 1-(3-methoxybenzyl)-3-substituted thiourea compound, and optionally a sunscreeen composition, are also provided.Type: ApplicationFiled: November 29, 2000Publication date: July 18, 2002Applicant: Fan Tech, Ltd.Inventors: Alan Wohlman, Anthony J. O'Lenick
-
Patent number: 6414030Abstract: Substituted benzenesulfonylureas and -thioureas of the formula I in which R1, R2, E, X, Y and Z have the meanings described herein, show effects on the autonomous nervous system. The invention relates to the use of the compounds of the formula I in the treatment and prophylaxis of dysfunctions of the autonomous nervous system, in particular of vagal dysfunctions, for example in the case of cardiovascular diseases. The invention also relates to the use of compounds of the formula I in combination with beta-receptor blockers and to products and pharmaceutical preparations which comprise at least one compound of the formula I and at least one beta-receptor blocker, and to novel compounds.Type: GrantFiled: November 9, 2001Date of Patent: July 2, 2002Assignee: Aventis Pharma Deutschland, GmbHInventors: Klaus Wirth, Heinrich Christian Englert, Helmut Bohn, Heinz Gögelein, Holger Heitsch, Uwe Gerlach
-
Publication number: 20020065299Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus. Parkinson's Disease, neuronal and cardiac ischemia. Huntington's disease and stroke.Type: ApplicationFiled: August 22, 2001Publication date: May 30, 2002Inventors: Soumitra S. Ghosh, Scott W. Miller, Robert E. Davis, Walter H. Moos
-
Patent number: 6362228Abstract: Novel phenylethyl-thiourea (PHET) compounds as inhibitors of reverse transcriptase and effective agents for the treatment of HIV infection, including mutant, drug-sensitive, drug-resistant, and multi-drug resistant strains of HIV.Type: GrantFiled: December 20, 2000Date of Patent: March 26, 2002Assignee: Parker Hughes InstituteInventors: Faith M. Uckun, Taracad K. Ventatachalam
-
Patent number: 6316478Abstract: This invention relates to novel spiro compound derivatives of benzoisothiazolyl-urea and -thiourea and compositions thereof. These compounds are useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).Type: GrantFiled: March 3, 2000Date of Patent: November 13, 2001Assignee: SmithKline Beecham CorporationInventors: Katherine L. Widdowson, Hong Nie
-
Patent number: 6316503Abstract: The invention provides compounds, compositions and methods for modulating the effects of LXR in a cell. The compounds and compositions are useful both as diagnostic indicators of LXR function and as pharmacologically active agents. The compounds and compositions find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.Type: GrantFiled: March 14, 2000Date of Patent: November 13, 2001Assignee: Tularik Inc.Inventors: Leping Li, Julio C. Medina, Kevin Lustig, Bei Shan, Hirohiko Hasegawa, Serena T. Cutler, Jiwen Liu, Liusheng Zhu
-
Patent number: 6313172Abstract: Methods and compositions for the treatment of pain using this area derivatives. Particularly disclosed are new compositions for the treatment of chronic pain, and methods for their use.Type: GrantFiled: April 13, 2000Date of Patent: November 6, 2001Assignee: Allergan Sales, Inc.Inventors: Ken Chow, Daniel W. Gil, Wenkui Ken Fang, Michael E. Garst, Larry A. Wheeler
-
Publication number: 20010021378Abstract: There are described a flowable composition for controlling harmful insects and representatives of the order Acarina, comprising at least one pesticidally active compound, one or more signal substances selected from the group consisting of pheromones, kairomones and attractants, a UV absorber or a UV absorber mixture and, if appropriate, one or more additives selected from the group consisting of viscosity-regulating thickeners, fillers, solvents and other formulation auxiliaries,Type: ApplicationFiled: February 22, 2001Publication date: September 13, 2001Inventors: Dieter Hofer, Max Angst, Pierre-Joseph Charmillot
-
Patent number: 6271261Abstract: Novel IL-8 receptor antagonists and methods of using them are provided.Type: GrantFiled: December 17, 1998Date of Patent: August 7, 2001Assignee: SmithKline Beecham CorporationInventor: Katherine L Widdowson
-
Patent number: 6255349Abstract: Compounds having the formula: wherein R1-R5 are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 carbon members, aryl, heteroaryl, halogen, —CN, —NO2, —CO2R6, —COR6, —OR6, —SR6, —SOR6, —SO2R6, —CONR7R8, —NR6N(R7R8), —N(R7R8) or W—Y—(CH2)n—Z provided that at least one of R1-R5 is not hydrogen; or R2 and R3or R3 and R4, taken together form a 3 to 7 membered heterocycloalkyl or 3 to 7 membered heteroaryl; R6 and R7 are independently hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, or aryl; R8 is hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 members, aryl or heteroaryl, or R7 anType: GrantFiled: November 22, 1999Date of Patent: July 3, 2001Assignee: American Home Products CorporationInventors: Jonathan Bloom, Kevin Curran, Martin DiGrandi, Russell Dushin, Stanley Lang, Emily Norton, Adma Ross, Bryan O'Hara
-
Patent number: 6207715Abstract: Compounds of the formula: are useful in the treatment of diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses, Epstein-Barr virus, varicella-zoster virus, human herpesviruses-6 and -7, and Kaposi herpes virus.Type: GrantFiled: November 22, 1999Date of Patent: March 27, 2001Assignee: American Home Products CorporationInventors: Jonathan Bloom, Kevin Curran, Martin DiGrandi, Russell Dushin, Stanley Lang, Emily Norton, Adma Ross, Bryan O'Hara
-
Patent number: 6187799Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.Type: GrantFiled: May 22, 1998Date of Patent: February 13, 2001Assignees: Onyx Pharmaceuticals, Bayer CorporationInventors: Jill E Wood, Hanno Wild, Daniel H Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum
-
Patent number: 6093742Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.Type: GrantFiled: June 27, 1997Date of Patent: July 25, 2000Assignee: Vertex Pharmaceuticals, Inc.Inventors: Francesco Gerald Salituro, Guy W. Bemis, Jeremy Green, James L. Kofron
-
Patent number: 6054590Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of phenyl derivatives of imidazolone compounds of Formula I. ##STR1## As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.Type: GrantFiled: March 3, 1999Date of Patent: April 25, 2000Assignee: Bristol-Myers Squibb CompanyInventors: Graham S. Poindexter, Ildiko Antal, Leah M. Giupponi, Robert H. Stoffel, Kevin Gillman, Mendi Higgins
-
Patent number: 6034102Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering a therapeutically effective amount of a compound of formula I.Type: GrantFiled: October 21, 1997Date of Patent: March 7, 2000Assignee: Pfizer IncInventor: Robert J. Aiello
-
Patent number: 5977177Abstract: This invention relates to substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them.Substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## exhibit effects on the cardiovascular system.Type: GrantFiled: June 4, 1998Date of Patent: November 2, 1999Assignee: Hoechst AktiengesellschaftInventors: Heinrich Englert, Uwe Gerlach, Dieter Mania, Heinz Gogelein, Joachim Kaiser
-
Patent number: 5958983Abstract: The present invention relates to polyaromatic compounds having useful antiviral activity against viruses of the herpes family, to a composition containing them, and to a method of using them for the treatment of herpes viruses infections.Type: GrantFiled: April 1, 1998Date of Patent: September 28, 1999Assignee: Pharmacia & Upjohn CompanyInventors: Michael R. Barbachyn, Fred L. Homa, Antonio Monge, Esteban Santiago, Juan J. Martinez-Irujo, Maria Font
-
Patent number: 5952386Abstract: The present invention provides dihalopropene compounds of the general formula: ##STR1## wherein R.sub.1 is C.sub.1 -C.sub.10 alkyl or the like; L is C(.dbd.O)NH or the like; R.sub.2, R.sub.3 and R.sub.4 are independently halogen or the like; R.sub.5, R.sub.6 and R.sub.7 are independently hydrogen or the like; m is an integer of 0 to 4; n is an integer of 0 to 2; X is chlorine or the like; Y is oxygen or the like; and Z is oxygen or the like, which have excellent insecticidal activity so that they are satisfactorily effective for the control of noxious insects.Type: GrantFiled: September 24, 1997Date of Patent: September 14, 1999Assignee: Sumitomo Chemical Company, LimitedInventors: Sanshiro Matsuo, Taro Hirose, Keiichi Izumi, Masaya Suzuki, Noriyasu Sakamoto, Kazunori Tsushima, Shigeru Saito, Hirotaka Takano
-
Patent number: 5929117Abstract: Cyano and carboxy derivatives of substituted styrenes are inhibitors of tumor necrosis factor .alpha., nuclear factor .kappa.B, and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. A typical embodiment is 3,3-bis-(3,4-dimethoxyphenyl)acrylonitrile.Type: GrantFiled: August 11, 1997Date of Patent: July 27, 1999Assignee: Celgene CorporationInventors: George W. Muller, Mary Shire
-
Patent number: 5928633Abstract: A material with excellent selective absorption of super antigens. Said material contains urea bonds or thiourea bonds and remains active even in a high protein concentration solution in the neutral region, Activity remains after sterilization. Also provided is a body fluid purifying column for eliminating or detoxification of super antigens. In addition to that, this invention provides a wound dressing material with super antigen adsorbing properties.Type: GrantFiled: May 13, 1996Date of Patent: July 27, 1999Assignee: Toray Industries, Inc.Inventors: Mayumi Fukuyama, Keishi Miwa, Kazuo Ishikawa
-
Patent number: 5886044Abstract: This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).Type: GrantFiled: March 20, 1996Date of Patent: March 23, 1999Assignee: SmithKline Beecham CorporationInventors: Katherine Louisa Widdowson, Daniel Frank Veber, Anthony Joseph Jurewicz, Robert Phillip Hertzberg, Melvin Clarence Rutledge, Jr.
-
Patent number: 5880155Abstract: This invention relates to substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them.Substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## exhibit effects on the cardiovascular system.Type: GrantFiled: February 15, 1996Date of Patent: March 9, 1999Assignee: Hoechst AktiengesellschaftInventors: Heinrich Englert, Uwe Gerlach, Dieter Mania, Heinz Gogelein, Joachim Kaiser
-
Patent number: 5780512Abstract: The invention relates to a compounds selected from these of formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3 and A are as defined in the description, and a medicinal product containing the same useful for treating a melatoninergic disorder.Type: GrantFiled: March 26, 1997Date of Patent: July 14, 1998Assignee: Adir et CompagnieInventors: Daniel Lesieur, Eric Fourmaintraux, Patrick Depreux, Philippe Delagrange, Pierre Renard, Beatrice Guardiola-Lemaitre
-
Patent number: 5776980Abstract: Benzenesulfonylureas and -thioureas of the formula I ##STR1## where R(1) is H or (fluoro)methyl, R(2) is H, Hal or (fluoro)(mercapto)alk(oxy)yl, E is O or S; Y is --?CR(3).sub.2 !.sub.n --, where R(3)=H or alkyl and n=1-4, X is H, Hal or alkyl and Z is Hal, NO.sub.2 or alk(yl)oxy, are described.The compounds I are used for treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrhythmia, and can therefore be used as antiarrhythmics. They are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.Type: GrantFiled: November 7, 1996Date of Patent: July 7, 1998Assignee: Hoechst AktiengesellschaftInventors: Heinrich Englert, Dieter Mania, Jens Hartung, Heinz Gogelein, Joachim Kaiser, Wolfgang Linz, David Wettlaufer
-
Patent number: 5773459Abstract: The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.Type: GrantFiled: June 7, 1995Date of Patent: June 30, 1998Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Gerald McMahon
-
Patent number: 5712312Abstract: The invention relates to a compound selected from these of formula (I): ##STR1## in which R.sub.7, R.sub.8, Y, n and A are as defined in the description, and medicinal product containing the same useful for treating a disorder of the melatoninergic system.Type: GrantFiled: April 12, 1996Date of Patent: January 27, 1998Assignee: Adir et CompagnieInventors: Michel Langlois, Monique Mathe-Allainmat, Philippe Delagrange, Pierre Renard, Beatrice Guardiola
-
Patent number: 5698596Abstract: Substituted benzenesulfonylureas and -thioureas--processes for their preparation and their use as pharmaceuticalsBenzenesulfonylureas and -thioureas of the formula I ##STR1## where R(1) is H or (fluoro)methyl, R(2) is H, Hal or (fluoro)(mercapto)alk(oxy)yl, E is O or S; Y is --?CR(3).sub.2 !.sub.n --, where R(3)=H or alkyl and n=1-4, X is H, Hal or alkyl and Z is Hal, NO.sub.2 or alk(yl)oxy, are described.The compounds I are used for treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrhythmia, and can therefore be used as antiarrhythmics. They are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.Type: GrantFiled: September 3, 1996Date of Patent: December 16, 1997Assignee: Hoechst AktiengesellschaftInventors: Heinrich Englert, Dieter Mania, Jens Hartung, Heinz Gogelein, Joachim Kaiser, Wolfgang Linz, David Wettlaufer
-
Patent number: 5696138Abstract: A compound having the formula ##STR1## or a pharmaceutically acceptable salt thereof, whereinX, Z, Y, A, D, E, F, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.11, R.sup.12 have the meanings set forth in the specification, pharmaceutical compositions comprising the same, and a method of treating therewith.The compounds are useful as potassium channel openers.Type: GrantFiled: December 27, 1995Date of Patent: December 9, 1997Assignee: NeuroSearch A/SInventors: S.o slashed.ren-Peter Olesen, Peter Moldt, Ove Pedersen
-
Patent number: 5668180Abstract: A compound selected from those of formula (I): ##STR1## in which A, R, Y, R.sup.1, R.sup.2 and R.sup.3 are as defined in the description,and a medicinal product containing the same useful for treating a disorder of the melatoninergic system.Type: GrantFiled: May 30, 1996Date of Patent: September 16, 1997Assignee: Adir Et CompagnieInventors: Daniel Lesieur, Patrick Depreux, Veronique Leclerc, Philippe Delagrange, Pierre Renard
-
Patent number: 5614550Abstract: Compounds of formula (I) are provided: ##STR1## wherein: R.sup.1 represents an alkyl group; or a group of formula (II), (III), (IV) or (V): ##STR2## and wherein the groups R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are hydrogen or various organic groups; and pharmaceutically acceptable salts thereof; as well as methods for the preparation of such compounds and their use in the treatment and prophylaxis of hypercholesteremia and arteriosclerosis.Type: GrantFiled: February 27, 1996Date of Patent: March 25, 1997Assignee: Sankyo Company, LimitedInventors: Akira Yoshida, Koza Oda, Sadao Ishihara, Fujio Saito, Hiroyuki Koike, Teiichiro Koga, Eiichi Kitazawa, Hiroshi Kogen, Ichiro Hayakawa
-
Patent number: 5574069Abstract: Benzenesulfonylureas and -thioureas of the formula I ##STR1## where R(1) is H or (fluoro)methyl, R(2) is H, Hal or (fluoro) (mercapto) alk (oxy) yl, E is O or S; Y is --[CR(3).sub.2 ]n-, where R(3)=H or alkyl and n=1-4, X is H, Hal or alkyl and Z is Hal, NO.sub.2 or alk(yl)oxy, are described.The compounds I are used for treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrhythmia, and can therefore be used as antiarrhythmics. They are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.Type: GrantFiled: February 23, 1995Date of Patent: November 12, 1996Assignee: Hoechst AktiengesellschaftInventors: Heinrich Englert, Dieter Mania, Jens Hartung, Heinz Gogelein, Joachim Kaiser, Wolfgang Linz, David Wettlaufer
-
Patent number: 5534529Abstract: Compounds of formula (I) are provided: ##STR1## wherein: R.sup.1 represents an alkyl group; or a group of formula (II), (III), (IV) or (V): ##STR2## and wherein the groups R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are hydrogen or various organic groups; and pharmaceutically acceptable salts thereof; as well as methods for the preparation of such compounds and their use in the treatment and prophylaxis of hypercholesteremia and arteriosclerosis.Type: GrantFiled: June 28, 1994Date of Patent: July 9, 1996Assignee: Sankyo Company, LimitedInventors: Akira Yoshida, Koza Oda, Sadao Ishihara, Takashi Kasai, Fujio Saito, Hiroyuki Koike, Teiichiro Koga, Eiichi Kitazawa, Hiroshi Kogen, Ichiro Hayakawa
-
Patent number: 5449689Abstract: A compound selected from those of formula (I): ##STR1## in which the meanings of R, R.sub.1, R.sub.2 and X are as defined in the specification, andmedicinal products containing the same which are useful in treating or in preventing a disorder of the melatoninergic system.Type: GrantFiled: December 20, 1994Date of Patent: September 12, 1995Assignee: Adir et CompagnieInventors: Daniel Lesieur, Said Yous, Patrick Depreux, Gerard Adam, Pierre Renard, Bruno Pfeiffer, Beatrice Guardiola-Lemaitre